www.CardioCareLive.com The Virtual Congress on Cardiovascular Disease Translating Science into Practice: Recent Advances Across the Spectrum of Cardiology Care Presented by the Johns Hopkins University School of Medicine. Supported by educational grants from Abbott Laboratories, AstraZeneca, Daiichi Sankyo, Inc, Lilly USA, LLC, Roche Diagnostics, Sanofi-Aventis, St. Jude Medical and Thoratec Corporation. Tuition Complimentary Date of Release: May 14, 2010 Date of Expiration: May 14, 2011 Estimated Time to Completion Each activity will take approximately sixty minutes to complete, for a total of 15 hours. Course Director Roger S. Blumenthal, MD, Professor of Medicine, Division of Cardiology at The Johns Hopkins University School of Medicine, Director, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Accreditation Statement The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statements The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 15.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of the four sessions designated for CEU credit, as highlighted on the agenda, will provide up to four home study (H) CE credit (4.0 CEU), and will be available upon successful completion of the program. Please note that each knowledge-based session will provide a statement for one (1.0) home study (H) CE credit. Successful completion includes participating in the program, completing a program evaluation form and a post- test with a score of at least 70%. If your score is less than 70% on the post-test, you will be allowed to complete the post-test one additional time. ACPE Program Numbers: 064-999-10-225-H01-P,064-999-10-226-H01-P, 064-999-10-227-H01-P, 064-999- 10-228-H01-P Release Date: May 14, 2010 Expiration Date May 14, 2011 Grievance Policy: A participant, sponsor, faculty member or other individual wanting to file a grievance with respect to any aspect of a program sponsored or co-sponsored by the UTCOP may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review. American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 15 hours of Category 1 credit for completing this program. This activity has been reviewed and is acceptable for up to 12.5 Elective credits by the American Academy of Family Physicians. American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 CME Credit(s)™ from organizations accredited by ACCME American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 CME Credit(s)™ from organizations accredited by ACCME Johns Hopkins Statement of Responsibility The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity. Intended Audience Cardiologists, primary care and family physicians, endocrinologists, cardiac imaging specialists, nurses, diabetes educators, physician assistants, pharmacists, and other healthcare professionals. Prerequisites There are no prerequisites. Statement of Need Cardiovascular (CV) risk was identified as one of the top priority health care conditions. Our goal is to provide the opportunity for physicians to learn and connect with world-class experts in cardiology and thousands of their peers in real time - helping to improve the care of patients with CV risk worldwide. Cardiovascular disease (CVD) is the leading cause of death in the US, primarily due to the effects of heart disease and stroke. it is estimated that 785,000 Americans will have a new coronary attack in 2010 and approximately 795,000 will experience a new or recurrent stroke. Learning Objectives After attending this activity, the participant will demonstrate the ability to: • Interpret and apply recent guidelines to the management of their patients with hypertension, dyslipidemia, and diabetes. Choosing the appropriate combinations of medical therapies for each patient and using expert recommended strategies to optimize patient compliance • Identify and manage atherosclerotic conditions using medical and interventional strategies that apply current evidence-based best practice • Apply recent guideline changes and utilize new therapies to design individualized management plans for patients experiencing acute coronary syndromes • Choose and utilize cardiovascular risk scoring systems that are appropriate and effective decision-making tools for specific patient populations within their practices • Design effective therapeutic plans for atrial fibrillation patients based on recent clinical evidence and expert recommended guidelines • Assess new medical and interventional therapies for heart failure and incorporate them into current evidence- based management practices Course Format Sessions are approximately sixty minutes and will be delivered in the form of video webcasts from faculty at www.CardioCareLive.com. If you have participated in any of the live sessions, you will not be eligible to receive on-demand credit for that particular session. We encourage you to review all sessions, regardless of your previous participation. Post-Test and Evaluation After each presentation participants will be presented with a post-test evaluation. Upon completion of both, participants receiving a grade of 70% or more will receive a CME certificate via email and US mail. Physicians must document amount of time they spent in the activity. Disclaimer Statement The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients. Expiration Date The expiration date for access to enduring materials is May 14, 2011, or one year from the end date of live event, which is May 14, 2010. Internet CME Policy The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request. Full Disclosure Policy Affecting CME Activities As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following: NAME COMPANY Grants/Research Support: Biosense Webster Hugh Calkins, MD Consultant: Sanofi Aventis; Ablation Frontiers, Biosense Webster; Medtronic; Cyber Heart Honorarium: Boston Scientific Grant/Research Support: Accumetrics; AstraZeneca; Bristol-Myers Squibb/Sanofi Aventis Partnership; GlaxoSmithKline; Intekrin Therapeutics; Merck; Novartis; Takeda Christopher Cannon, Consulting: Scientific Advisory Board (but funds donated to charity) ; Bristol-Myers MD Squibb/Sanofi Aventis Other Financial/Material Support: Clinical Advisor, equity in Automedics Medical Systems Grants/Research Support: Novartis; Daiichi-Sankyo Keith Ferdinand, MD, Consultant: Novartis; Daiichi-Sankyo; Forest; AstraZeneca; Merck FACC, FAHA Honorarium: Novartis; AstraZeneca Speakers Bureau: AstraZeneca; Forest Other Financial/Material Support: Both Mayo Clinic and I have a financial interest in David R. Holmes, Jr., technology related to this research. That technology has been licensed to Atritech MD and Mayo Clinic and I have a contractual right to receive future royalties from this license. To date, no royalties have been received by either Mayo Clinic or me. Grants/Research Support: Roche; Siemens; Critical Diagnostics James Januzzi, MD Consultant: Roche; Critical Diagnostics Grants/Research Support: Pfizer, Inc.; Abbott, Inc.; Schering Plough; SmithKlineBeecham Peter O. Kwiterovich, Consultant: Merck; Schering Plough MD Honorarium: Merck; Schering Plough Speaker Bureau: Merck (non-commercial talks only) Grants/Research Support: Thoratec; Heartware Leslie Miller, MD Consultant: Heartware ? unpaid; Thoratec Honorarium: Thoratec Richard Nesto, MD Consultant: GlaxoSmithKline; Sanofi-Aventis Grants/Research Support: Astra Zeneca; Novartis; Sanofi Aventis Paul Ridker, MD, Consultant: Vascular Biogenics; Siemens; Novartis; Astra Zeneca; Merck MPH Patent Royalties: Brigham and Women?s Hospital Grants/Research Support: Astra Zeneca; Sanofi Aventis; Schering-Plough Marc Sabatine, MD, Scientific Advisory Board: Bristol-Myers Squibb; Sanofi Aventis MPH Honorarium: Eli Lilly Honorarium: Bristol-Myers Squibb/Sanofi Aventis; AstraZeneca; Boston Scientific; Gregg W. Stone, MD Abbott Vascular Matthew Weir, MD Ad-Hoc Scientific Advisor: Novartis; Daiichi-Sankyo; Boehringer-Ingelheim Nathan Wong, PhD Grants/Research Support: Bristol-Myers Squibb; Novartis; Forest Pharmaceuticals All other speakers have indicated that they have not received financial support for consultation, research, evaluation or have a financial interest relevant to their presentation. Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s). OFF-LABEL PRODUCT DISCUSSION The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products: NAME COMPANY Christopher Cannon, MD ticagrelor David R. Holmes, Jr., MD Atritech, Watchman Device James Januzzi, MD natriuretic peptides Leslie Miller, MD HeartWare device Marc Sabatine, MD, MPH clopidogrel, prasugrel, ticagrelor All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.
Pages to are hidden for
"CCL-May2010-On-Demand-CME-Content"Please download to view full document